April 07, 2011 09:23 ET

Equity Research on Perrigo Co. and Auxilium Pharmaceuticals Inc. -- Drug Related Products Industry Strong at the Moment

NEW YORK, NY--(Marketwire - April 7, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Related Products industry and are offering free analytical research on Perrigo Co. (NASDAQ: PRGO) and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Register with us today at to have free access to this research or speak to one of our pros at

Status changes, new products and new partnerships are fueling strong revenues for many companies in the drug related products industry. Get instant analyses of Perrigo Co. and Auxilium Pharmaceuticals Inc. from live, real-time experts standing by at There is no commitment to join.

Several over-the-counter drug manufacturers will benefit from product status changes in the coming months and in some cases, years. The status changes will result from prescription drugs being approved by the Food and Drug Administration for over-the-counter sales. This should bode well for companies with strong interests in the over-the-counter arena, such as Perrigo Company. Perrigo Co. report is accessible for free by registering today at is the Ultimate Trading Environment for investors. If you are considering owning Perrigo Co. and Auxilium Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing. 

Forging new partnerships has also been important for companies in the industry. Auxilium Pharmaceutical Inc. recent deal with a Japanese pharmaceutical company will net it $15 million initially and as much as $247 million in potential future payments based on certain quotas. Auxilium Pharmaceuticals Inc. report is accessible for free by registering today at  

Moving forward, successful status changes will be key for companies in the over-the-counter drug market. Increased competition has also re-emphasized maintaining a steady pipeline of new products or creating new partnerships. Companies transitioning the most prescription drugs to over-the-counter while developing their own products could be best positioned for growth in 2011.

The two Drug Related Products stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information